Comparative Effectiveness Research: Betahistine add-on Therapy with Epley's Manoeuvre Versus Epley's Manoeuvre Alone in Treating Posterior BPPV Patients

被引:0
|
作者
Singh, Garima [1 ]
Aggarwal, Ankita [1 ]
Sahni, Dimple [1 ]
Kumar Sharma, Dinesh [1 ]
Yadav, Vishav [1 ]
Bhagat, Sanjeev [1 ]
机构
[1] Govt Med Coll Patiala, Dept Otolaryngol Head & neck Surg, Patiala, India
关键词
BPPV; vertigo; Epley's manoeuvre; betahistine; PAROXYSMAL POSITIONAL VERTIGO; DIZZINESS; LIFE;
D O I
10.1007/s12070-022-03369-7
中图分类号
R61 [外科手术学];
学科分类号
摘要
Introduction: Benign paroxysmal positional vertigo is one of the common vestibular disorders encountered in ENT clinics with accompanying vertigo. Study to evaluate the additive effects of betahistine on Epley's manoeuvre in treating posterior BPPV patients. Material and Methods: Prospective study was conducted on 50 patients of posterior BPPV diagnosed by the Dix Hallpike test. Subjects were divided into Group A which received the Betahistine therapy along with the canalith repositioning technique (Epley's manoeuvre) and the second group (Group B) which received the Epley's manoeuvre alone. The patients were assessed at 1 week and 4 weeks by Visual Analogue Scale (VAS), Dizziness Handicap Inventory (DHI) and Short Form 36 (SF-36). Results: At the end of 4 weeks, 2 patients in group A (E + B) had positive Dix-Hallpike and 23(92%) had negative Dix-Hallpike, while 11 patients in group B (E) had positive Dix-Hallpike and 14 (56%) had negative Dix-Hallpike with P value < 0.001. The Mean baseline (T0) Visual Analogue Scale (VAS) score in group A (E + B) was 8.60 +/- 1.080 and in group B (E) was 8.92 +/- 0.996. Post-treatment VAS score was significantly lower in both the groups and was significantly lower in group A(E + B) than in group B (E) (0.680 +/- 1.930 vs. 3.96 +/- 3.587, respectively, p-value < 0.001). The Mean baseline (T0) Dizziness Handicap Inventory (DHI) scores were similar in groups A and B (77.36 +/- 9.49 vs. 80.00 +/- 8.9, respectively, p = 0.271). After treatment, the DHI values were significantly lower in both groups. Group A had a better DHI score than group B (10.56 +/- 17.12 vs. 44.72 +/- 27.35, p < 0.001). The mean baseline (T0) Short Form 36 (SF-36) scores were also similar in groups A and B (19.53 +/- 6.85 vs. 18.79 +/- 5.50, p = 0.823). Post-treatment of 4 weeks, the SF-36 score significantly improved in both the groups and significantly improved in group A than group B (84.27 +/- 17.28 vs. 46.53 +/- 24.53, p < 0.001). Conclusion: Betahistine therapy in conjunction with Epley's manoeuvre leads to better symptom control and is more effective than Epley's alone in treating BPPV patients.
引用
收藏
页码:204 / 209
页数:6
相关论文
共 32 条
  • [21] Safety and effectiveness of istradefylline as add-on therapy to levodopa in patients with Parkinson's disease: Final report of a post-marketing surveillance study in Japan
    Takahashi, Makio
    Ito, Satoru
    Tsuji, Yukie
    Horiguchi, Shuji
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2022, 443
  • [22] Effectiveness of Kabat Technique versus Mirror Book Therapy on clinical and electrophysiological parameters in patients with Bell’s palsy: a comparative interventional study
    Priyanshi K. Patel
    Aparna A. Bachkaniwala
    Bulletin of Faculty of Physical Therapy, 29 (1)
  • [23] Comparative effectiveness of teclistamab versus real-world physician's choice of therapy for patients with triple-class exposed relapsed/refractory multiple myeloma
    Krishnan, Amrita
    Nooka, Ajay
    Chari, Ajai
    Garfall, Alfred
    Martin, Thomas
    Nair, Sandhya
    Lin, Xiwu
    Qi, Keqin
    Londhe, Anil
    Pei, Lixia
    Ammann, Eric
    Kobos, Rachel
    Smit, Jennifer
    Parekh, Trilok
    Marshall, Alexander
    Slavcev, Mary
    Usmani, Saad
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S174 - S174
  • [24] COMPARATIVE EFFECTIVENESS OF TECLISTAMAB VERSUS REAL-WORLD PHYSICIAN'S CHOICE OF THERAPY (RWPC) FOR PATIENTS WITH TRIPLE-CLASS EXPOSED (TCE) RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Krishnan, A.
    Nooka, A.
    Chari, A.
    Garfall, A. L.
    Martin, T.
    Nair, S.
    Lin, X.
    Qi, K.
    Londhe, A.
    Pei, L.
    Ammann, E.
    Chastain, K.
    Parekh, T.
    Marshall, A.
    Slavcev, M.
    Usmani, S. Z.
    VALUE IN HEALTH, 2023, 26 (12) : S37 - S37
  • [25] Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma
    Martin, Thomas
    Krishnan, Amrita
    Yong, Kwee
    Weisel, Katja
    Mehra, Maneesha
    Nair, Sandhya
    Qi, Keqin
    Londhe, Anil
    Diels, Joris
    Crivera, Concetta
    Jackson, Carolyn C.
    Olyslager, Yunsi
    Vogel, Martin
    Schecter, Jordan M.
    Banerjee, Arnob
    Valluri, Satish
    Usmani, Saad Z.
    Berdeja, Jesus G.
    Jagannath, Sundar
    EJHAEM, 2022, 3 (01): : 97 - 108
  • [26] Comparative effectiveness of higher adalimumab maintenance therapy versus standard dose in anti-tumor necrosis factor experienced Crohn's disease patients: A propensity-score matched cohort analysis
    Narula, Neeraj
    Wong, Emily C. L.
    AlRamdan, Raed
    Bualbanat, Hasan
    Marshall, John K.
    Steinhart, A. Hillary
    Greener, Tomer
    Silverberg, Mark S.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 (10) : 2803 - 2812
  • [27] Cost-effectiveness of speech and language therapy plus scalp acupuncture versus speech and language therapy alone for community-based patients with Broca's aphasia after stroke: a post hoc analysis of data from a randomised controlled trial
    Liu, Zhizhen
    Huang, Jia
    Xu, Ying
    Wu, Jingsong
    Tao, Jing
    Chen, Lidian
    BMJ OPEN, 2021, 11 (09):
  • [28] Comparative real-world effectiveness and persistence of vedolizumab versus anti-TNF therapy in biologic-naive patients with Crohn's Disease with Propensity Score adjustment: Maintenance phase results at week-52 from the prospective VEDOIBD study
    Di Giuseppe, R.
    Plachta-Danielzik, S.
    Bokemeyer, B.
    Efken, P.
    Mohl, W.
    Hoffstadt, M.
    Krause, T.
    Schweitzer, A.
    Schnoy, E.
    Atreya, R.
    Teich, N.
    Trentmann, L.
    Ehehalt, R.
    Franzenburg, S.
    Hartmann, P.
    Schreiber, S.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I120 - I121
  • [29] Comparative real-world effectiveness and persistence of vedolizumab versus anti-TNF therapy in biologic-naive patients with Crohn's disease with propensity score adjustment: two-year maintenance phase results from the prospective VEDO-IBD study
    Bokemeyer, B.
    Plachta-Danielzik, S.
    Efken, P.
    Mohl, W.
    Hoffstadt, M.
    Krause, T.
    Schweitzer, A.
    Schnoy, E.
    Atreya, R.
    Teich, N.
    Trentmann, L.
    Ehehalt, R.
    Franzenburg, S.
    Hartmann, P.
    di Giuseppe, R.
    Schreiber, S.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 543 - 543
  • [30] R-CHOP, Followed by High Dose Therapy and Autologous Stem Cell Rescue (HDT/ASCR), and R-Hypercvad Have Equivalent Progression-Free Survival and Are Superior to R-CHOP Alone in Younger Patients with Mantle Cell Lymphoma: a Comparative Effectiveness Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma Outcomes Database Project
    LaCasce, Ann
    Vandergrift, Jonathan L.
    Rodriguez, Maria A.
    Crosby, Allison L.
    Lepisto, Eva M.
    Czuczman, Myron S.
    Nademanee, Auayporn P.
    Blayney, Douglas W.
    Gordon, Leo I.
    Millenson, Michael
    Vanderplas, Ann
    Abel, Gregory A.
    Zelenetz, Andrew D.
    Friedberg, Jonathan W.
    BLOOD, 2009, 114 (22) : 167 - 168